Luminary's Pipeline
Non-viral Cell Therapies
- Luminary is developing a broad pipeline of non-viral cell therapies via in-licensed advancements from notable academic institutions’ cell therapy teams.
- Our product pipeline will focus on underserved cancers and autoimmune disorders.
- At this time, Luminary’s investigational therapies can only be accessed through participation in a clinical trial.
| Program | Type | Indication | Research | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|---|
| LMY-920 BAFF |
CAR-T |
B-cell Malignancies
Autoimmune Disorders
|
|||||
| LMY-475 Mesothelin |
TCR | Solid Tumors | |||||
| LMY-232 Multiple Targets |
Universal Receptor |
Solid Tumors
Autoimmune Disorders
|
Targeting multiple B cell markers on tumor and inflammatory cells
LMY-920’s BAFF target has the potential to preserve early B cells
Depiction of our proprietary B cell activating factor (BAFF) directed third-generation chimeric antigen receptor (CAR). LMY-920’s BAFF targets multiple B cell markers on tumor and inflammatory cells including the BAFF receptor (BAFF-R), BCMA, and TACI.
